Anzeige
Mehr »
Mittwoch, 25.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DK8U | ISIN: LU2458332611 | Ticker-Symbol: Z45
Frankfurt
25.06.25 | 15:29
7,900 Euro
+1,02 % +0,080
1-Jahres-Chart
ALVOTECH Chart 1 Jahr
5-Tage-Chart
ALVOTECH 5-Tage-Chart
RealtimeGeldBriefZeit
7,8408,02017:48

Aktuelle News zur ALVOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15:18Alvotech reports positive results in study for Xolair biosimilar3
10:06Alvotech: Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair (omalizumab)137REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines...
► Artikel lesen
ALVOTECH Aktie jetzt für 0€ handeln
MoBayer's Eylea market grip set to slip as Alvotech biosimilar closes in91
MoAlvotech - 6-K, Report of foreign issuer3
MoEuropean Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea (aflibercept)323REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
► Artikel lesen
12.06.Alvotech - 6-K, Report of foreign issuer16
11.06.Alvotech schließt Privatplatzierung mit 40 institutionellen Investoren ab8
11.06.Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors641Alvotech (NASDAQ: ALVO, ALVO-SDB, the "Company"), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion...
► Artikel lesen
11.06.Alvotech auf Goldman Sachs Konferenz: Strategisches Wachstum bei Biosimilars5
06.06.Alvotech and Dr. Reddy's partner for Keytruda biosimilar3
05.06.Alvotech - 6-K, Report of foreign issuer4
05.06.Dr. Reddy's stock rises on biosimilar collaboration with Alvotech3
05.06.Dr. Reddy's Laboratories Ltd.: Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab)363Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ("Alvotech"), and Dr. Reddy's Laboratories Ltd., (BSE:...
► Artikel lesen
05.06.Alvotech and Dr. Reddy's partner to co-develop biosimilar candidate for Keytruda (pembrolizumab) 8
05.06.Alvotech, Dr. Reddy's Partner To Develop Biosimilar Candidate To Keytruda8
05.06.Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab)247HYDERABAD, INDIA & REYKJAVIK, ICELAND (June 5, 2025) - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide...
► Artikel lesen
05.06.Dr Reddys Lab gains on global biosimilar deal with Alvotech11
05.06.Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million164THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH...
► Artikel lesen
04.06.Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares337THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA...
► Artikel lesen
04.06.Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia237Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane...
► Artikel lesen
Weiter >>
93 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1